NASDAQ:LSB Lakeshore Biopharma (LSB) Stock Price, News & Analysis $2.38 -0.31 (-11.52%) Closing price 03:58 PM EasternExtended Trading$2.59 +0.21 (+8.82%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Lakeshore Biopharma Stock (NASDAQ:LSB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lakeshore Biopharma alerts:Sign Up Key Stats Today's Range$2.31▼$2.8850-Day Range$2.27▼$3.7052-Week Range$1.88▼$11.20Volume3,708 shsAverage Volume15,007 shsMarket Capitalization$22.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Read More… Lakeshore Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScoreLSB MarketRank™: Lakeshore Biopharma scored higher than 33% of companies evaluated by MarketBeat, and ranked 822nd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lakeshore Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioLakeshore Biopharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lakeshore Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the float of Lakeshore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeshore Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakeshore Biopharma has recently decreased by 42.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakeshore Biopharma does not currently pay a dividend.Dividend GrowthLakeshore Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.41% of the float of Lakeshore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeshore Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakeshore Biopharma has recently decreased by 42.62%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.96 News SentimentLakeshore Biopharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lakeshore Biopharma this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Lakeshore Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakeshore Biopharma insiders have not sold or bought any company stock.Percentage Held by Institutions52.64% of the stock of Lakeshore Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lakeshore Biopharma's insider trading history. Receive LSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakeshore Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LSB Stock News HeadlinesLakeshore Biopharma (LSB) Expected to Announce Quarterly Earnings on MondayJanuary 25, 2025 | americanbankingnews.comLakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial ApprovalDecember 19, 2024 | markets.businessinsider.com22x better than Bitcoin… WITHOUT cryptoWe’re on the verge of a massive paradigm shift. And it will leave millions of people behind… including you, perhaps. The legendary former hedge fund manager Larry Benedict has discovered a different way to make money from Bitcoin.January 30, 2025 | Brownstone Research (Ad)LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year GuidanceDecember 19, 2024 | prnewswire.comLakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 13, 2024 | finanznachrichten.deLakeShore Biopharma Faces Challenges Amid Criminal Probe into Former ChairmanDecember 12, 2024 | markets.businessinsider.comLakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 12, 2024 | globenewswire.comLakeShore Biopharma Co Ltd Ordinary SharesNovember 23, 2024 | morningstar.comSee More Headlines LSB Stock Analysis - Frequently Asked Questions How have LSB shares performed this year? Lakeshore Biopharma's stock was trading at $3.46 on January 1st, 2025. Since then, LSB shares have decreased by 31.2% and is now trading at $2.38. View the best growth stocks for 2025 here. When did Lakeshore Biopharma's stock split? Lakeshore Biopharma's stock reverse split before market open on Friday, October 4th 2024. The 1-10 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Lakeshore Biopharma? Shares of LSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lakeshore Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lakeshore Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Today1/30/2025Fiscal Year End3/31/2025Next Earnings (Estimated)4/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSB Previous SymbolNASDAQ:LSB CUSIPN/A CIK1946399 WebN/A Phone17327133678FaxN/AEmployees773Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.13 Current Ratio1.17 Quick Ratio0.90 Sales & Book Value Annual Sales$80.82 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value$8.86 per share Price / Book0.27Miscellaneous Outstanding Shares9,310,000Free FloatN/AMarket Cap$22.16 million OptionableN/A Beta0.71 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:LSB) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.